| Literature DB >> 27065865 |
Muhammad Ayaz1, Muhammad Junaid1, Farhat Ullah1, Abdul Sadiq1, Fazal Subhan2, Mir Azam Khan1, Waqar Ahmad1, Gowhar Ali2, Muhammad Imran3, Sajjad Ahmad1.
Abstract
Polygonum hydropiper is used as anti-cancer and anti-rheumatic agent in folk medicine. This study was designed to investigate the anti-angiogenic, anti-tumor, and cytotoxic potentials of different solvent extracts and isolated saponins. Samples were analyzed using GC, Gas Chromatography-Mass Spectrometry (GC-MS) to identify major and bioactive compounds. Quantitation of antiangiogenesis for the plant's samples including methanolic extract (Ph.Cr), its subsequent fractions; n-hexane (Ph.Hex), chloroform (Ph.Chf), ethyl acetate (Ph.EtAc), n-Butanol (Ph.Bt), aqueous (Ph.Aq), saponins (Ph.Sp) were performed using the chick embryo chorioallantoic membrane (CAM) assay. Potato disc anti-tumor assay was performed on Agrobacterium tumefaciens containing tumor inducing plasmid. Cytotoxicity was performed against Artemia salina and mouse embryonic fibroblast NIH/3T3 cell line following contact toxicity and MTT cells viability assays, respectively. The GC-MS analysis of Ph.Cr, Ph.Hex, Ph.Chf, Ph.Bt, and Ph.EtAc identified 126, 124, 153, 131, and 164 compounds, respectively. In anti-angiogenic assay, Ph.Chf, Ph.Sp, Ph.EtAc, and Ph.Cr exhibited highest activity with IC50 of 28.65, 19.21, 88.75, and 461.53 μg/ml, respectively. In anti-tumor assay, Ph.Sp, Ph.Chf, Ph.EtAc, and Ph.Cr were most potent with IC50 of 18.39, 73.81, 217.19, and 342.53 μg/ml, respectively. In MTT cells viability assay, Ph.Chf, Ph.EtAc, Ph.Sp were most active causing 79.00, 72.50, and 71.50% cytotoxicity, respectively, at 1000 μg/ml with the LD50 of 140, 160, and 175 μg/ml, respectively. In overall study, Ph.Chf and Ph.Sp have shown overwhelming results which signifies their potentials as sources of therapeutic agents against cancer.Entities:
Keywords: MTT assay; Polygonum hydropiper; anti-angiogenic; chorioallantoic membrane assay; fibroblast cell line; saponin
Year: 2016 PMID: 27065865 PMCID: PMC4814464 DOI: 10.3389/fphar.2016.00074
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Figure 1Cluster analysis based on IC Cluster analysis and dendogram based on IC50 of various samples of polygonam hydropiper in CAM assay. (B) Cluster analysis and dendogram based on IC50 of various samples of polygonam hydropiper in anti-tumor assay. (C) Cluster analysis and dendogram based on IC50 of samples in cytotoxic activity.
Figure 2Linear correlation of IC. (A) Linear correlation of IC50 of anti-angiogenic and antitumor activities of P. hydropiper. (B) Linear correlation of IC50 of cytotoxic and antitumor activities of P. hydropiper.
Results of anti-angiogenic assay of .
| Ph.Cr | 29.25 ± 0.20 | 36.32 ± 3.50 | 40.50 ± 0.58 | 45.96 ± 1.01 | 52.33 ± 0.33 | 65.33 ± 0.88 | 461.53 |
| Ph.Hex | 21.93 ± 0.49 | 25.32 ± 1.30 | 26.66 ± 0.89 | 32.50 ± 0.86 | 39.83 ± 1.36 | 43.53 ± 0.46 | 1538.46 |
| Ph.Chf | 51.00 ± 1.50 | 55.00 ± 2.80 | 61.33 ± 0.68 | 60.93 ± 1.21 | 69.96 ± 2.66 | 78.63 ± 1.67 | 28.65 |
| Ph.EtAc | 43.50 ± 0.58 | 48.50 ± 0.86 | 52.70 ± 1.60 | 56.03 ± 0.82 | 61.00 ± 1.15 | 69.43 ± 1.15 | 88.75 |
| Ph.Bt | 24.03 ± 0.23 | 27.00 ± 1.15 | 28.33 ± 0.33 | 39.33 ± 0.88 | 52.66 ± 1.45 | 61.46 ± 2.43 | 438.82 |
| Ph.Aq | 19.74 ± 0.68 | 26.61 ± 1.70 | 31.38 ± 0.68 | 37.33 ± 0.33 | 41.00 ± 1.15 | 52.83 ± 1.36 | 915.34 |
| Ph.Sp | 53.64 ± 1.60 | 57.22 ± 0.23 | 59.87 ± 0.26 | 64.10 ± 1.15 | 68.43 ± 0.97 | 76.96 ± 1.01ns | 19.21 |
Dexamethasone was used as positive control having IC50 value of 11.68 μg/ml.
Values significantly different when compared to standard drug
p < 0.05,
p < 0.01, and
p < 0.001 at 90% confidence interval.
ns, Values not significantly different in comparison to standard drug.
Anti-tumor investigations of extracts and saponins isolated from .
| Ph.Cr | 1000 | 21.66 ± 0.66 | 72.20 ± 2.2 | 342.53 |
| 500 | 17.66 ± 0.33 | 58.86 ± 1.1 | ||
| 250 | 13.00 ± 1.15 | 43.33 ± 3.8 | ||
| 125 | 09.33 ± 0.88 | 31.10 ± 2.9 | ||
| 62.5 | 09.33 ± 0.33 | 31.10 ± 1.1 | ||
| 31.25 | 06.00 ± 0.57 | 20.00 ± 1.9 | ||
| Ph.Hex | 1000 | 17.00 ± 0.00 | 56.66 ± 0.0 | 657.72 |
| 500 | 14.33 ± 0.88 | 47.76 ± 2.9 | ||
| 250 | 11.33 ± 0.33 | 37.76 ± 1.1 | ||
| 125 | 08.66 ± 0.88 | 28.86 ± 2.9 | ||
| 62.5 | 07.00 ± 1.73 | 23.33 ± 5.7 | ||
| 31.25 | 05.33 ± 1.45 | 17.76 ± 4.8 | ||
| Ph.Chf | 1000 | 25.66 ± 0.66 | 85.53 ± 2.2 | 73.81 |
| 500 | 21.33 ± 0.88 | 71.10 ± 2.9 | ||
| 250 | 17.00 ± 0.57 | 56.66 ± 1.9 | ||
| 125 | 16.66 ± 0.00 | 55.53 ± 0.0 | ||
| 62.50 | 14.33 ± 0.88 | 47.76 ± 2.9 | ||
| 31.25 | 14.33 ± 0.33 | 47.76 ± 1.1 | ||
| Ph.EtAc | 1000 | 24.00 ± 0.57 | 80.00 ± 1.9 | 217.19 |
| 500 | 19.33 ± 0.33 | 64.43 ± 1.1 | ||
| 250 | 15.66 ± 0.33 | 52.20 ± 1.1 | ||
| 125 | 13.00 ± 1.15 | 44.33 ± 3.8 | ||
| 62.50 | 11.66 ± 0.66 | 38.66 ± 2.2 | ||
| 31.25 | 10.00 ± 0.00 | 33.33 ± 0.0 | ||
| Ph.Bt | 1000 | 20.00 ± 0.57 | 66.66 ± 1.9 | 439.83 |
| 500 | 16.00 ± 0.57 | 53.33 ± 1.9 | ||
| 250 | 11.33 ± 0.88 | 37.76 ± 2.9 | ||
| 125 | 10.00 ± 0.57 | 33.33 ± 1.9 | ||
| 62.50 | 07.66 ± 0.33 | 25.53 ± 1.1 | ||
| 31.25 | 06.00 ± 0.57 | 20.00 ± 1.9 | ||
| Ph.Aq | 1000 | 16.66 ± 0.66 | 55.53 ± 2.2 | 881.12 |
| 500 | 11.00 ± 0.00 | 36.66 ± 0.0 | ||
| 250 | 09.00 ± 1.15 | 30.00 ± 3.8 | ||
| 1250 | 07.00 ± 1.73 | 23.33 ± 5.7 | ||
| 62.5 | 06.33 ± 1.45 | 21.10 ± 4.8 | ||
| 31.25 | 04.33 ± 0.88 | 14.43 ± 2.9 | ||
| Ph.Sp | 1000 | 27.00 ± 0.57 | 90.00 ± 1.9ns | 18.39 |
| 500 | 24.00 ± 0.00 | 80.00 ± 0.0ns | ||
| 250 | 22.33 ± 0.33 | 74.43 ± 1.1 | ||
| 125 | 21.00 ± 1.15 | 70.00 ± 3.8 | ||
| 62.50 | 18.00 ± 0.57 | 60.00 ± 1.9 | ||
| 31.25 | 17.33 ± 0.88 | 57.76 ± 2.9 |
Vincristine sulfate was used as positive control having IC50 < 0.1 μg/ml. Values significantly different as compare to positive control,
P < 0.05,
P < 0.01,
:P < 0.001.
ns, Values not significantly different in comparison to standard drug.
Results of antibacterial activity (Disc diffusion) and (MICs) against .
| Ph.Cr | NA | NA | NA | 16.66 ± 0.83 | NA |
| Ph.Hex | NA | NA | NA | NA | NA |
| Ph.Chf | NA | NA | NA | NA | NA |
| Ph.EtAc | NA | NA | NA | NA | NA |
| Ph.Bt | NA | NA | NA | NA | NA |
| Ph.Aq | NA | NA | NA | NA | NA |
| Ph.Sp | NA | NA | 11.00 ± 0.15 | 13.00 ± 0.50 | 1523.33 ± 8.81 |
| Ceftriaxone | 15.66 ± 0.66 | 29.33 ± 0.88 | 24.00 ± 1.00 | 27.00 ± 0.57 | 17.50 ± 1.44 |
| Cefotaxime | 18.00 ± 0.57 | 22.00 ± 1.00 | 2626.33 ± 0.33 | 31.00 ± 1.52 | 6.66 ± 1.66 |
NA, Not active at the tested concentration.
Results of brine shrimps cytotoxicity assay performed on .
| Ph.Cr | 1000 | 30 | 28.67 ± 0.33 | 95.56 ± 1.1 | 56.73 |
| 500 | 30 | 27.00 ± 0.58 | 90.00 ± 1.9ns | ||
| 250 | 30 | 24.67 ± 0.88 | 82.23 ± 2.9 | ||
| 125 | 30 | 20.33 ± 1.20 | 67.76 ± 4.0 | ||
| 62.50 | 30 | 16.00 ± 1.15 | 53.33 ± 3.8 | ||
| 31.25 | 30 | 11.33 ± 0.88 | 37.76 ± 2.9 | ||
| Ph.Hex | 1000 | 30 | 22.00 ± 1.00 | 73.33 ± 3.3 | 182.29 |
| 500 | 30 | 19.33 ± 0.33 | 64.43 ± 1.1 | ||
| 250 | 30 | 16.67 ± 0.67 | 55.56 ± 2.2 | ||
| 125 | 30 | 13.00 ± 0.00 | 43.33 ± 0.0 | ||
| 62.50 | 30 | 07.33 ± 1.20 | 34.43 ± 4.0 | ||
| 31.25 | 30 | 05.67 ± 0.33 | 18.90 ± 1.1 | ||
| Ph.Chf | 1000 | 30 | 30.00 ± 0.00 | 100.0 ± 0.0ns | 31.71 |
| 500 | 30 | 27.33 ± 0.88 | 91.10 ± 2.9 | ||
| 250 | 30 | 27.67 ± 0.67 | 92.23 ± 2.2ns | ||
| 125 | 30 | 25.67 ± 0.33 | 85.56 ± 1.1ns | ||
| 62.50 | 30 | 19.00 ± 0.58 | 63.33 ± 1.9ns | ||
| 31.25 | 30 | 15.00 ± 1.15 | 50.00 ± 3.8ns | ||
| Ph.EtAc | 1000 | 30 | 30.00 ± 0.00 | 100.0 ± 0.0ns | 47.91 |
| 500 | 30 | 28.67 ± 0.88 | 95.56 ± 2.9 | ||
| 250 | 30 | 25.33 ± 1.20 | 84.43 ± 4.0 | ||
| 125 | 30 | 24.00 ± 1.00 | 80.00 ± 3.3 | ||
| 62.50 | 30 | 18.33 ± 1.20 | 61.00 ± 4.0 | ||
| 31.25 | 30 | 11.33 ± 0.33 | 37.76 ± 1.1 | ||
| Ph.Bt | 1000 | 30 | 30.00 ± 0.00 | 100.0 ± 0.0ns | 36.42 |
| 500 | 30 | 26.67 ± 0.33 | 88.90 ± 1.1 | ||
| 250 | 30 | 26.00 ± 1.00 | 86.66 ± 3.3 | ||
| 125 | 30 | 21.67 ± 0.33 | 72.23 ± 1.1 | ||
| 62.50 | 30 | 17.00 ± 0.00 | 56.66 ± 0.0 | ||
| 31.25 | 30 | 14.67 ± 0.67 | 48.90 ± 2.2ns | ||
| Ph.Aq | 1000 | 30 | 24.33 ± 0.33 | 81.10 ± 1.1 | 196.95 |
| 500 | 30 | 21.33 ± 1.20 | 71.10 ± 4.0 | ||
| 250 | 30 | 16.33 ± 0.88 | 54.43 ± 2.9 | ||
| 125 | 30 | 12.67 ± 0.67 | 42.23 ± 2.2 | ||
| 62.50 | 30 | 09.67 ± 0.88 | 32.23 ± 2.9 | ||
| 31.25 | 30 | 04.33 ± 0.33 | 14.43 ± 1.1 | ||
| Ph.Sp | 1000 | 30 | 30.00 ± 0.00 | 100.0 ± 0.0 | 31.25 |
| 500 | 30 | 30.00 ± 0.00 | 100.0 ± 0.0 | ||
| 250 | 30 | 28.00 ± 0.58 | 93.33 ± 1.9 | ||
| 125 | 30 | 26.33 ± 0.33 | 87.76 ± 1.1 | ||
| 62.50 | 30 | 19.33 ± 0.67 | 64.43 ± 2.2 | ||
| 31.25 | 30 | 15.00 ± 0.00 | 50.00 ± 0.0 | ||
| Negative control | 30 | 0 | 0 | —- |
Values significantly different as compare to positive control,
P < 0.05,
P < 0.01,
P < 0.001.
ns, Values not significantly different in comparison to standard drug.
Results of cytotoxicty study using mouse embryonic fibroblast NIH/3T3 cell lines.
| Ph.Cr | 1000 | 30.76 ± 0.50 | 69.24 | 280 |
| 500 | 41.45 ± 0.66 | 58.55 | ||
| 250 | 53.00 ± 1.00 | 47.00 | ||
| 125 | 60.00 ± 2.30 | 40.00 | ||
| 62.5 | 65.00 ± 0.00 | 35.00 | ||
| Ph.Chf | 1000 | 21.00 ± 0.57 | 79.00 | 140 |
| 500 | 26.00 ± 1.15 | 74.00 | ||
| 250 | 43.00 ± 0.00 | 57.00 | ||
| 125 | 48.00 ± 0.00 | 52.00 | ||
| 62.5 | 55.00 ± 0.50 | 45.00 | ||
| Ph.Hex | 1000 | 41.00 ± 0.16 | 59.00 | 560 |
| 500 | 55.00 ± 1.15 | 45.00 | ||
| 250 | 67.50 ± 0.44 | 32.50 | ||
| 125 | 72.00 ± 0.00 | 28.00 | ||
| 62.5 | 78.00 ± 0.00 | 22.00 | ||
| Ph.EtAc | 1000 | 27.50 ± 1.04 | 72.50 | 160 |
| 500 | 37.00 ± 1.15 | 63.00 | ||
| 250 | 45.00 ± 0.16 | 55.00 | ||
| 125 | 58.00 ± 0.00 | 42.00 | ||
| 62.5 | 66.00 ± 0.00 | 34.00 | ||
| Ph.Bt | 1000 | 45.00 ± 0.58 | 55.00 | 780 |
| 500 | 58.33 ± 0.88 | 41.67 | ||
| 250 | 71.00 ± 1.15 | 29.00 | ||
| 125 | 79.00 ± 0.57 | 21.00 | ||
| 62.5 | 84.00 ± 0.00 | 16.00 | ||
| Ph.Sp | 1000 | 28.50 ± 1.00 | 71.50 | 175 |
| 500 | 34.66 ± 1.33 | 65.34 | ||
| 250 | 46.00 ± 0.00 | 54.00 | ||
| 125 | 55.00 ± 1.15 | 45.00 | ||
| 62.5 | 67.00 ± 0.00 | 33.00 | ||
| Ph.Aq | 1000 | 46.66 ± 1.20 | 53.34 | 790 |
| 500 | 50.66 ± 0.88 | 49.34 | ||
| 250 | 58.00 ± 1.15 | 42.00 | ||
| 125 | 69.00 ± 0.57 | 31.00 | ||
| 62.5 | 81.00 ± 0.00 | 19.00 | ||
| Negative control | —– | 100 | 0 | —- |
Positive control (Standard drug) etoposide, LD50 was 5.46 μg/ml.
Values significantly different when compared to standard drug
p < 0.001.
Figure 3GC–MS chromatograms of Ph.Cr (A), Ph.Hex (B), Ph.EtAc (C), Ph.Bt (D), and Ph.Chf (E) isolated from .
Figure 5Structures of active anticancer compounds identified in GC–MS analysis of Succinimide (B) Pyrocatechol (C) Humulene (D) Caryophyllene oxide (E) Dihydrojasmone (F) Farnesol (G) Methyl p-coumarate (H) Myristic acid (I) Dodecyl acrylate (J) Stearic acid (K) Lauramide (L) Tricosane (M) Capsaicine (N) Clionasterol.